Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of 2-Picolinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.50 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.47 |
| ▸ | AGTR1 known ✓ | P30556 | 1/20 | 0.47 |
| ▸ | KCNK3 known ✓ | O14649 | 1/20 | 0.47 |
| ▸ | KCNK9 known ✓ | Q9NPC2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.95 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.95 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.95 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.95 |
| ▸ | CES2 | O00748 | 1/20 | 0.67 |
| ▸ | CES1 | P23141 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | GSK3B | P49841 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2-Picolinic Acid SCHEMBL30779159 | 1.00 | LMNA (0.95) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| 2-Picolinic Acid SCHEMBL337643 | 1.00 | LMNA (0.95) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| 2-Picolinic Acid SCHEMBL29761294 | 1.00 | LMNA (0.95) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| 2-Picolinic Acid SCHEMBL890376 | 1.00 | LMNA (0.95) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| 2-Picolinic Acid SCHEMBL28128752 | 1.00 | LMNA (0.95) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| 2-Picolinic Acid SCHEMBL2164674 | 0.98 | LMNA (0.91) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| 2-Picolinic Acid SCHEMBL22288254 | 0.98 | LMNA (0.91) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| 2-Picolinic Acid SCHEMBL28256814 | 0.98 | LMNA (0.91) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| 2-Picolinic Acid SCHEMBL674837 | 0.98 | LMNA (1.00) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| 2-Picolinic Acid SCHEMBL29368665 | 0.98 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 402 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119899082-A | Method for using nitrogen-oxygen ligand modified low-content ruthenium-based catalyst in acetylene hydrochlorination | 南京工业大学 | 2025-04-29 | — | — | CN | claimed |
| US-20240425517-A1 | NOVEL COMPOUND FOR DEGRADATION OF TARGET PROTEIN OR POLYPEPTIDE BY POLYUBIQUITINATION | PRAZER THERAPEUTICS INC. (KR) | 2024-12-26 | — | — | US | claimed |
| CN-118812550-A | Indole naphthalene photopyran derivatives Process for preparing color-changing compound | 江苏科洛明新材料科技有限公司 | 2024-10-22 | — | — | CN | claimed |
| WO-2023191400-A1 | ETHYL PIPERIDINE TRIAZOLO TRIAZINE DERIVATIVES, SYNTHESIS METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME FOR PREVENTION OR TREATMENT OF CANCER | 에이치케이이노엔 주식회사 | 2023-10-05 | — | — | WO | claimed |
| CN-115787126-A | Method for preparing high-performance organic fiber based on pyridine hydrochloride | 安徽威驰化工有限责任公司 | 2023-03-14 | — | — | CN | claimed |
| CN-114716371-A | N-containing active center metal organic catalyst for synthesizing cyclic carbonate and preparation method and application thereof | 上海应用技术大学 | 2022-07-08 | — | — | CN | claimed |
| CN-114539138-A | Fluorescent probe for environmental detection and preparation method and application thereof | 中大检测(湖南)股份有限公司 | 2022-05-27 | — | — | CN | claimed |
| CN-110713600-A | Preparation method of self-healing silicon elastomer based on metal coordination bond-hydrogen bond double crosslinking and elastomer | 北京化工大学 | 2020-01-21 | — | — | CN | claimed |
| CN-106458923-B | Heterocyclic compound | 株式会社大熊制药 | 2019-09-10 | — | — | CN | claimed |
| CN-105218436-B | A method of preparing 4- Chloro-2-Pyridyle methyl formate | 济南诚汇双达化工有限公司 | 2019-02-05 | — | — | CN | claimed |
| CN-104781244-A | Process for the preparation of (1S,4S,5S)-4-bromo-6-oxabicyclo[3.2.1]octan-7-one | DAIICHI SANKYO CO LTD | 2015-07-15 | — | — | CN | claimed |
| CN-104761571-A | Synthesis method of edoxaban | SHANDONG KEXING BIOPRODUCTS CO LTD | 2015-07-08 | — | — | CN | claimed |
| CN-103113427-B | Fructosevaline preparation method | NINGBO MEDICAL SYSTEM BIOTECHNOLOGY CO LTD | 2015-04-08 | — | — | CN | claimed |
| CN-103113427-A | Fructosevaline preparation method | NINGBO MEDICAL BIOLOG TECHNOLOGY CO LTD | 2013-05-22 | — | — | CN | claimed |
| CN-103097384-A | Substituted imidazo [1,2-a ] pyrimidines and pyridines | BAYER IP GMBH | 2013-05-08 | — | — | CN | claimed |
| WO-2010089773-A2 | PROCESS FOR PREPARATION OF NITROPYRIDINE DERIVATIVES | INDOCO REMEDIES LIMITED (IN) | 2010-08-12 | — | — | WO | claimed |
| CN-1893941-A | Fused-ring compounds and use thereof as drugs | JAPAN TOBACCO INC (JP) | 2007-01-10 | — | — | CN | claimed |
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
| CN-1483320-A | Heterocyclic ring contained methylamine cyanoacrylate compound and weeding activity | 南开大学 | 2004-03-24 | — | — | CN | claimed |
| US-5166352-A | Pyridinecarboxylic acid chlorides from (trichloromethyl)pyridines | DOWELANCO (US) | 1992-11-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425517-A1 | NOVEL COMPOUND FOR DEGRADATION OF TARGET PROTEIN OR POLYPEPTIDE BY POLYUBIQUITINATION | ADRM1, SUMO1, SUMO2 | PTGS2 4352/4885OPRK1 4134/4885AGTR1 3005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.